Form 8-K - Current report:
SEC Accession No. 0001213900-20-015271
Filing Date
2020-06-18
Accepted
2020-06-18 16:39:33
Documents
8
Period of Report
2020-06-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea123189-8k_actiniumpharma.htm 8-K 36737
2 FORM OF PRE-FUNDED WARRANT ea123189ex4-1_actinium.htm EX-4.1 100004
3 EXHIBIT 5.1 ea123189ex5-1_actinium.htm EX-5.1 13435
4 FORM OF SECURITIES PURCHASE AGREEMENT ea123189ex10-1_actinium.htm EX-10.1 197519
5 PRESS RELEASE, DATED JUNE 16, 2020 ea123189ex99-1_actinium.htm EX-99.1 10738
6 PRESS RELEASE, DATED JUNE 16, 2020 ea123189ex99-2_actinium.htm EX-99.2 11096
7 GRAPHIC ex99-1_001.jpg GRAPHIC 10166
8 GRAPHIC ex99-2_001.jpg GRAPHIC 10166
  Complete submission text file 0001213900-20-015271.txt   399045
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 20973155
SIC: 2834 Pharmaceutical Preparations